Immunovaccine Inc.
TSX : IMV

Immunovaccine Inc.

April 15, 2015 07:05 ET

Immunovaccine to Present at American Association for Cancer Research (AACR) 2015 Annual Meeting

Presentation Highlights Increased Anti-Tumor Efficacy When Combining anti-PD-1 with DepoVax™-based Vaccines

HALIFAX, NOVA SCOTIA--(Marketwired - April 15, 2015) - Immunovaccine Inc. ("Immunovaccine" or the "Company") (TSX:IMV), a clinical stage vaccine and immunotherapy company, announced today that a poster, highlighting the combination of DepoVax-based vaccines with an anti-PD-1 monoclonal antibody, will be presented at the 2015 Annual Meeting of the American Association for Cancer Research (AACR). The Annual Meeting will be held in Philadelphia, April 18-22, 2015. The data shows that DepoVax-based vaccines, when combined with anti-PD-1 therapy, lead to stronger anti-tumor activity than the anti-PD-1 therapy alone in multiple animal models.

The poster entitled: "Multi-modal treatment with peptide vaccine, metronomic cyclophosphamide and anti-PD-1 monoclonal antibody provides effective control of tumors in multiple models," describes the use of DepoVax-based immunotherapy combined with low dose cyclophosphamide and the checkpoint inhibitor anti-PD-1, in two independent animal models including an ovarian cancer model. The poster will be presented on Monday, April 20, 2015, 1:00 PM - 5:00 PM, at Poster Board #20 in Section 26 of the Pennsylvania Convention Center.

"This data provides a strong rationale for combining our DepoVax-based cancer immunotherapies with checkpoint inhibitors that can modulate the tumor environment," said Marc Mansour, Chief Executive Officer of Immunovaccine. "We believe potent immunotherapy combinations that include a highly immunogenic vaccine, such as DPX-Survivac, are well suited for targeting difficult to treat cancers."

There has been considerable interest in novel immunotherapies targeting molecules such as PD-1, highlighted by the recent accelerated approvals of Keytruda from Merck and Opdivo from Bristol-Myers Squibb in multiple cancer indications. A current industry focus is to combine these compounds with other immunotherapies, in particular T cell activating therapies, to further extend their clinical benefit.

Last month, Immunovaccine initiated a Phase 2 clinical trial with its T cell activation therapy DPX-Survivac in combination with low dose cyclophosphamide as an immune modulator in recurrent lymphoma, with an additional randomized Phase 2 trial planned in ovarian cancer. Previous Phase 1 studies in ovarian cancer have demonstrated strong and durable activation of T cells that recognize the vaccine target survivin. Patients with a robust immune response to DPX-Survivac showed a trend of delayed disease progression, which may be attributed to the therapy. The majority of ovarian cancer patients enrolled in these studies were in remission with no evidence of disease. One patient with measurable and stable disease, however, achieved a 43% reduction in tumor size, demonstrating a durable clinical benefit associated with the DPX-Survivac therapy.

About DPX-Survivac

DPX-Survivac consists of survivin-based peptide antigens formulated in the DepoVax™ adjuvanting platform. Survivin has been recognized by the National Cancer Institute (NCI) as a promising tumor-associated antigen (TAA) because of its therapeutic potential and its cancer specificity. Survivin is broadly over-expressed in solid tumors and blood cancers including ovarian, breast, colon and lung cancers, among others. Survivin plays an essential role in antagonizing apoptosis, supporting tumor-associated angiogenesis, and promoting resistance to various anti-cancer therapies. Survivin is also a prognostic factor for many cancers and it is found in high percentage of cancer patients.

The DPX-Survivac vaccine is thought to work by eliciting a cytotoxic T cell immune response against cells presenting survivin peptides on HLA class I molecules. This targeted therapy attempts to use the immune system to actively search for tumor cells expressing survivin and destroy them.

About DepoVaxDepoVax is a patented formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system, resulting in a strong, specific and sustained immune response with the potential for single-dose effectiveness. The DepoVax platform is flexible and can be used with a broad range of target antigens for preventative or therapeutic applications. The technology is designed to be commercially scalable, with the potential for years of shelf life stability.

About Immunovaccine

Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the Company's DepoVax platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 2 study with its lead cancer vaccine therapy, DPX-Survivac, in recurrent lymphoma. DPX-Survivac is expected to enter additional Phase 2 clinical studies in ovarian cancer and glioblastoma (brain cancer). The Company is also advancing an infectious disease pipeline including innovative vaccines for respiratory syncytial virus (RSV), anthrax and Ebola virus.

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future, is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.

Contact Information